Low-dose IL-2 immunotherapy demonstrates broad, disease-modifying effects by selectively expanding regulatory T cells (Tregs), offering a promising strategy across diverse diseases including autoimmunity, neurodegeneration, metabolic dysfunction, transplantation, and inflammatory disorders.